Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07133074 · ClinicalTrials.gov registry record · Phase 4
Allergy Delabeling in Antibiotic Stewardship - Intervention
A Phase 4 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 3,800
- Enrollment target
NCT07133074: Recruiting Phase 4 study, sponsored by Abramson Cancer Center at Penn Medicine.
NCT07133074 is a Phase 4 study that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 3,800 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (634% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07133074, a Phase 4 study, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 3,800 participants
- Enrollment target
Study Summary
The overall goal of the RENEW-IN intervention is to assess the impact of a BL allergy delabeling intervention on antibiotic use and clinical outcomes in patients with a hematologic malignancy.
Primary Outcome
Proportion of participants prescribed an antibiotic during index hospitalization, from enrollment in the study to hospital discharge or death, whichever occurs first
Interventions
- DIAGNOSTIC_TEST RENEW-IN Algorithm for assessment of a beta-lactam intervention
- OTHER EMR Review
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,800 participants |
| Start Date | 2026-04-20 |
| Est. Completion | 2029-11 |
| Phase | Phase 4 |
What NCT07133074 shows while recruiting
NCT07133074 is an interventional study that assigns participants to a tested intervention. Its 3,800 participants enrollment target places it among the larger protocols in the corpus, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (634% higher).
The record links to 0 conditions, and to 2 interventions - of which RENEW-IN Algorithm for assessment of a beta-lactam intervention is the first listed.
NCT07133074 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07133074 about?
NCT07133074 is a clinical study titled "Allergy Delabeling in Antibiotic Stewardship - Intervention". The overall goal of the RENEW-IN intervention is to assess the impact of a BL allergy delabeling intervention on antibiotic use and clinical outcomes in patients with a hematologic malignancy.
What is the current status of trial NCT07133074?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 3,800 participants. The study started on 2026-04-20. Estimated completion is 2029-11.
What interventions are being tested in trial NCT07133074?
The interventions under investigation include: RENEW-IN Algorithm for assessment of a beta-lactam intervention (DIAGNOSTIC_TEST), EMR Review (OTHER).
Who is sponsoring clinical trial NCT07133074?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07133074's enrollment target sits among peer trials
3,800 21st of 2000 higher than 1,980 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04573660 · 3,784 participants
Abbott Vascular Medical Device Registry
- NCT07087613 · 3,850 participants
Deep Learning Detection of Pulmonary Hypertension and Low Ejection Fraction Via Digital Stethoscope and 3-Lead ECG
- NCT06172660 · 3,750 participants
Real-World Effectiveness of Perinatal RSV Immunoprophylaxis
- NCT06298253 · 3,750 participants · NA
Behavioral Economics to Implement a Traffic Light Nutrition Ranking System: Study 2
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI